Research Article
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy
Table 3
Univariate analysis of clinical factors potentially associated diffuse disease progression.
| | Patients with limited disease progression | Patients with diffuse disease progression | |
| Age | | | | <65 | 56% | 60% | 0.95 | ≥65 | 44% | 40% | Phenotype | | | | Her2(+) | 26% | 16% | <0.04 | Her2(−) | 74% | 84% | Time to metastasis | | | | ≤6 months from initial Dx | 50% | 58% | 0.85 | >6 months from initial Dx | 50% | 42% | Longest time to progression | | | | ≤12 months | 50% | 42% | 0.85 | >12 months | 50% | 58% | # of metastatic sites | | | | ≤6 sites of disease | 44% | 20% | <0.04 | >6 sites of disease | 56% | 80% | Disease site | | | | Bone | 47% | 70% | <0.02 | Other | 53% | 30% |
|
|
displaying oligoprogression or oligometastases with progression at least once in their disease course.
|